SpringWorks Therapeutics Inc (SWTX)
44.86
+0.09
(+0.20%)
USD |
NASDAQ |
May 17, 16:00
44.86
0.00 (0.00%)
After-Hours: 20:00
SpringWorks Therapeutics Enterprise Value: 2.880B for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | 2.880B |
| May 15, 2024 | 2.912B |
| May 14, 2024 | 2.745B |
| May 13, 2024 | 2.633B |
| May 10, 2024 | 2.593B |
| May 09, 2024 | 2.745B |
| May 08, 2024 | 2.694B |
| May 07, 2024 | 2.953B |
| May 06, 2024 | 2.995B |
| May 03, 2024 | 2.905B |
| May 02, 2024 | 2.775B |
| May 01, 2024 | 3.034B |
| April 30, 2024 | 3.023B |
| April 29, 2024 | 3.005B |
| April 26, 2024 | 2.937B |
| April 25, 2024 | 2.837B |
| April 24, 2024 | 2.776B |
| April 23, 2024 | 2.822B |
| April 22, 2024 | 2.740B |
| April 19, 2024 | 2.533B |
| April 18, 2024 | 2.709B |
| April 17, 2024 | 2.830B |
| April 16, 2024 | 2.778B |
| April 15, 2024 | 2.712B |
| April 12, 2024 | 2.730B |
| Date | Value |
|---|---|
| April 11, 2024 | 2.830B |
| April 10, 2024 | 2.790B |
| April 09, 2024 | 2.838B |
| April 08, 2024 | 2.827B |
| April 05, 2024 | 2.858B |
| April 04, 2024 | 2.861B |
| April 03, 2024 | 2.987B |
| April 02, 2024 | 2.992B |
| April 01, 2024 | 3.090B |
| March 31, 2024 | 3.209B |
| March 28, 2024 | 3.166B |
| March 27, 2024 | 3.231B |
| March 26, 2024 | 3.165B |
| March 25, 2024 | 3.182B |
| March 22, 2024 | 3.268B |
| March 21, 2024 | 3.318B |
| March 20, 2024 | 3.229B |
| March 19, 2024 | 3.113B |
| March 18, 2024 | 3.094B |
| March 15, 2024 | 3.231B |
| March 14, 2024 | 3.172B |
| March 13, 2024 | 3.302B |
| March 12, 2024 | 3.192B |
| March 11, 2024 | 3.095B |
| March 08, 2024 | 3.289B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
419.10M
Minimum
Nov 14 2019
4.075B
Maximum
Feb 24 2021
1.893B
Average
1.485B
Median
Sep 03 2020
Enterprise Value Benchmarks
| Geron Corp | 1.953B |
| Verastem Inc | 259.27M |
| Karyopharm Therapeutics Inc | 156.15M |
| Syndax Pharmaceuticals Inc | 1.335B |
| Arvinas Inc | 1.029B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -87.38M |
| Revenue (Quarterly) | 21.01M |
| Total Expenses (Quarterly) | 114.94M |
| EPS Diluted (Quarterly) | -1.18 |
| Gross Profit Margin (Quarterly) | 94.28% |
| Profit Margin (Quarterly) | -416.0% |
| Earnings Yield | -11.48% |
| Normalized Earnings Yield | -11.48 |